Collagen is the major structural protein of the body and as such provides the framework for all tissues including skin, bone, tendon, cartilage, lung, cornea, and heart valve. Proper collagen biosynthesis requires a precise orchestration of a number of transcriptional and post-translation steps including regulation of type-specific collagen biosynthesis, hydroxylation of proline and lysine, glycosylation of hydroxylysine, disulfide bond formation, transport to the extracellular space, enzymatic excision of extension peptides, fibril formation, and cross-linking. Perturbation in this sequential biosynthetic scheme might be expected to result in structurally altered connective tissue and disease. Individual abnormalities in collagen biosynthesis have been described in patients presenting clinically with Ehlers-Danlos syndrome, osteogenesis imperfecta, and cutis laxa. We propose to study collagen biosynthesis in skin fibroblasts obtained from patients with these study collagen biosynthesis in skin fibroblasts obtained from patients with these and other inherited disorders of connective tissue. The following parameters of collagen biosynthesis will be measured: (1) type-specific collagen synthesis, (2) synthesis of procollagen and processing of procollagen, (3) synthesis of glycosylated hybroxylysine, (4) synthesis of reducible cross-links, (5) levels of lysyl hydroxylase prolyl hydroxylase and lysyl, (6) levels of collagen specific mRNA, and (7) structure of collagen genes. It is hoped that these studies will allow us to better understand these diseases at a biochemical level. Such understanding is a prerequisite for rational prenatal diagnosis, genetic counseling, and therapeutic management.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR017128-14
Application #
3154927
Study Section
General Medicine A Subcommittee 2 (GMA)
Project Start
1978-09-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
14
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Uzawa, Katsuhiro; Yeowell, Heather N; Yamamoto, Kazushi et al. (2003) Lysine hydroxylation of collagen in a fibroblast cell culture system. Biochem Biophys Res Commun 305:484-7
Yeowell, H N; Allen, J D; Walker, L C et al. (2000) Deletion of cysteine 369 in lysyl hydroxylase 1 eliminates enzyme activity and causes Ehlers-Danlos syndrome type VI. Matrix Biol 19:37-46
Yeowell, H N; Walker, L C (1999) Tissue specificity of a new splice form of the human lysyl hydroxylase 2 gene. Matrix Biol 18:179-87
Yeowell, H N; Walker, L C (1999) Prenatal exclusion of Ehlers-Danlos syndrome type VI by mutational analysis. Proc Assoc Am Physicians 111:57-62
Walker, L C; Marini, J C; Grange, D K et al. (1999) A patient with Ehlers-Danlos syndrome type VI is homozygous for a premature termination codon in exon 14 of the lysyl hydroxylase 1 gene. Mol Genet Metab 67:74-82
Yeowell, H N; Walker, L C; Murad, S et al. (1997) A common duplication in the lysyl hydroxylase gene of patients with Ehlers Danlos syndrome type VI results in preferential stimulation of lysyl hydroxylase activity and mRNA by hydralazine. Arch Biochem Biophys 347:126-31
Yeowell, H N; Walker, L C (1997) Ehlers-Danlos syndrome type VI results from a nonsense mutation and a splice site-mediated exon-skipping mutation in the lysyl hydroxylase gene. Proc Assoc Am Physicians 109:383-96
Krol, B J; Murad, S; Walker, L C et al. (1996) The expression of a functional, secreted human lysyl hydroxylase in a baculovirus system. J Invest Dermatol 106:11-6
Yeowell, H N; Walker, L C; Marshall, M K et al. (1995) The mRNA and the activity of lysyl hydroxylase are up-regulated by the administration of ascorbate and hydralazine to human skin fibroblasts from a patient with Ehlers-Danlos syndrome type VI. Arch Biochem Biophys 321:510-6
Ha, V T; Marshall, M K; Elsas, L J et al. (1994) A patient with Ehlers-Danlos syndrome type VI is a compound heterozygote for mutations in the lysyl hydroxylase gene. J Clin Invest 93:1716-21

Showing the most recent 10 out of 16 publications